Back to Hompage
Hebrew  |  English  
 
 
     
 
 
Homepage
Printer Friendly Version    
  My TASE  
 
NEXTGEN BIOMED LTD (In Maint)
Market Data Charts Historical Prices Statistics Profile Analysis & Ratios Disclosures
   Issuer No.   
Corporate No.
   Market Cap (23/03/2017)   
   1092   
   520044470   
    4,668 NIS thousands   
   TASE Supersector
   TASE Sector   
   TASE Subsector   
   Indices   
   High-Tech   
   Biomed   
   Biotechnology   
   Additional Indices   
  Contact Details :
  Phone : 09-9500555
  Fax : 077-3180015
  INFO@NEXTGEN-BIOMED.COM
   Interested Parties:
   Interested Parties:
List of Interested Parties  >
List of Securities  >
Indices  >
Financial Statements – Key Data (NIS thousands) **
 September 2016
IFRS
September 2015
IFRS
Yearly 2015
IFRS
Balance Sheet
Total Assets
6,447
3,209
2,470
Current Assets
6,443
3,178
2,464
Non Current Assets
4
31
6
Shareholders Equity
5,542
2,054
1,735
Of which Minority Interest
-82
-74
-75
Current Liabilities
874
1,144
722
Long-Term Liabilities
31
11
13
Profit & Loss Statement
Revenues
0
0
0
Gross Profit
0
0
0
Operating Income
-1,398
-4,204
-4,388
Income Before Tax
-1,383
-4,243
-4,371
Net Income
-1,383
-4,243
-4,350
Income Attributable to Shareholders
-1,390
-4,267
-4,325
Earnings per Share
-0.09
-0.68
-0.56
Additional Data
Dividends
0
0
0
Net cash flow generated by operating activities
-1,117
-3,317
-4,012
Financial Ratios
Market to book value
0.83
---
---
Price-Earning Ratio
Loss
---
---
Equity-Assets Ratio
87.2 %
---
73.3 %
Return on Equity
-37.4 %
---
-886.3 %
 Export Table Data 
Note: The financial statements data have been obtained from A-Online and they were compiled and processed by it. The data have not been examined or audited by the Stock Exchange and they are presented as given to the Stock Exchange by A-Online.
The binding data are those appearing in the financial statements published by the Company. Without derogating from the provisions of the use agreement , the Stock Exchange is not liable for any fault, error, mistake or inaccuracy in the data presented. Financial statements published in foreign currency are translated to NIS according to the exchange rate at the date of the financial statements.
Financial Ratios: Market Capitalization – as of end of previous trading day; Net income – attributable to the Shareholders (Trailing Twelve Months); Shareholders' Equity- attributable to the Shareholders (average 12 months start and end of period).